Nozomi MedAlliance was established in 2022 as the Japan base for Theranova, a San Francisco medical device incubator founded in 2006 by Dr. Daniel Burnett. Theranova has founded and incubated over a dozen companies and raised over $330 million in venture capital with multiple successful exits to date.

Nozomi will bring to Japan Theranova’s healthcare and longevity innovations, and will serve as a Japan-based hub for Japanese MedTech companies to participate in San Francisco Bay Area-style innovation, commercialization and global business development.

Nozomi’s first project is to commercialize Theranova’s Cardiospire in Japan. Cardiospire is a programmed medical device which fulfills the promise of low-risk, highly accurate, non-invasive hemodynamic and cardiopulmonary monitoring in the OR, ICU and at home. Cardiospire has the potential to deliver enormous healthcare cost savings to Japan.

Shungo ADACHI, Co-founder and Representative Director, has more than 15 years of experience in innovative healthcare management and policy development in Japan and overseas. He has had overall management responsibility for medical cluster projects, working with corporations and providing strategic planning for R&D and operations teams. To improve healthcare delivery, Shungo has introduced valuable new technologies to the healthcare policy and medical care system in Japan. He is an expert in DX (digital transformation) strategy and implementation in the healthcare sector. Shungo has advised Japanese pharmaceutical companies, major research institutions and European and US businesses. His passion is to develop a new ecosystem that supports Japan emerging as a global leader in elderly care.

Shungo holds an MPH degree from Kyoto University Graduate School of Medicine, School of Public Health, Department of Healthcare Economics and Quality Management.